Last Friday, the European Commission authorized the marketing of a new modification, the third, of the Spikevax vaccine against Covid-19, from the pharmaceutical company Moderna.
Spikevax
The marketing authorization was granted through an accelerated procedure, following a positive assessment by the European Medicines Agency.
In Portugal, vaccination will start on September 29 and will take place simultaneously in public pharmacies, for people aged 60 or over, and in health facilities of the National Health Service (SNS), for people under 60 and with risk diseases. .
On September 7, the European Center for Disease Prevention and Control (ECDC) warned of the recent increase in transmission of the Covid-19 virus in the European Union and the European Economic Area (EU/EEA).
“In recent weeks, signs of transmission of SARS-CoV-2 have increased from previously very low levels in the EU/EEA,” the European agency said in a statement.
Covid-19 is a pandemic respiratory disease caused by the coronavirus SARS-CoV-2, a type of virus discovered in China in late 2019 that has adopted several variants and subvariants, some more contagious than others.
Source: DN
